Drug Description in Trials / DrugBank / KEGG DRUG /

  

Search results

No. 薬物名（臨床試験情報から抽出） DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY 指定難病告示番号
15009111000001105----1件: 43 💬
2ALEMTUZUMAB1件: Alemtuzumab1件: Alemtuzumab 💬1件: CD52 💬-17件: 13, 15, 19, 20, 36, 43, 44, 46, 51, 60, 63, 65, 85, 96, 164, 283, 284 💬
3Avacopan1件: Avacopan1件: Avacopan 💬1件: C5AR1 💬6件: Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Staphylococcus aureus infection 💬3件: 43, 44, 222 💬
4Azathioprine1件: Azathioprine1件: Azathioprine 💬--21件: 6, 11, 13, 19, 35, 42, 43, 44, 45, 46, 49, 63, 65, 66, 85, 93, 94, 95, 96, 97, 162 💬
5BELIMUMAB1件: Belimumab1件: Belimumab 💬1件: TNFSF13B 💬4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬13件: 11, 13, 43, 44, 46, 49, 51, 53, 63, 66, 222, 296, 300 💬
6Belimumab 10 mg/kg1件: Belimumab1件: Belimumab 💬1件: TNFSF13B 💬4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬3件: 43, 46, 49 💬
7Benlysta1件: Belimumab1件: Belimumab 💬1件: TNFSF13B 💬4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬5件: 43, 49, 53, 66, 222 💬
8Benlysta 400 mg powder for concentrate for solution for infusion1件: Belimumab1件: Belimumab 💬1件: TNFSF13B 💬4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬2件: 43, 49 💬
9Benlysta 400mg polvere per concentrato per soluzione per infusione1件: Belimumab1件: Belimumab 💬1件: TNFSF13B 💬4件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬1件: 43 💬
10Blisibimod1件: Blisibimod1件: Blisibimod 💬--5件: 43, 44, 49, 63, 66 💬
11CCX168----5件: 43, 44, 66, 109, 222 💬
12CELLCEPT1件: Mycophenolate mofetil1件: Mycophenolate mofetil 💬2件: IMPDH1,
IMPDH2 💬		4件: Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Purine metabolism 💬5件: 11, 13, 42, 43, 49 💬
13CellCept (Mycophenolate Mofetil)2件: Mycophenolate mofetil,
Mycophenolic acid		2件: Mycophenolate mofetil ,
Mycophenolic acid 💬		2件: IMPDH1,
IMPDH2 💬		4件: Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Purine metabolism 💬2件: 42, 43 💬
14Chimeric monoclonal antibody, IgG4 subtype----2件: 43, 44 💬
15Corticosteroid----9件: 13, 42, 43, 44, 45, 66, 96, 97, 222 💬
16Corticosteroid and azathioprine1件: Azathioprine1件: Azathioprine 💬--4件: 42, 43, 44, 45 💬
17Cyclophosphamide1件: Cyclophosphamide2件: Cyclophosphamide ,
Cyclophosphamide 💬		--44件: 11, 13, 14, 16, 19, 20, 26, 28, 35, 36, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 52, 56, 60, 62, 65, 66, 84, 85, 93, 96, 162, 164, 172, 205, 222, 224, 256, 274, 283, 284, 285, 288, 326, 331 💬
18Cyclophosphamide, Azathioprine,prednisone,methylprednisolone4件: Azathioprine,
Cyclophosphamide,
Methylprednisolone,
Prednisone		5件: Azathioprine ,
Cyclophosphamide ,
Methylprednisolone ,
Prednisone ,
Cyclophosphamide 💬		1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬3件: 42, 43, 45 💬
19DELTACORTENE----2件: 43, 97 💬
20ENDOXAN----7件: 13, 28, 43, 44, 85, 96, 222 💬
21ENDOXAN BAXTER----3件: 13, 43, 96 💬
22Freeze-Dried Sulfonated Human Normal Immunoglobulin (GGS)1件: Human immunoglobulin G---3件: 14, 43, 45 💬
23GALEN® tablet----2件: 43, 44 💬
24Glucocorticoid (GC)----2件: 43, 44 💬
25Glucocorticoids----8件: 40, 41, 43, 44, 60, 62, 75, 300 💬
26Glucocorticoids (GC)----2件: 43, 44 💬
27Glucocorticoids - Reduced Dose----2件: 43, 44 💬
28Glucocorticoids - Standard Dose----2件: 43, 44 💬
29Glucocorticoids [Reduced Dose]----2件: 43, 44 💬
30Glucocorticoids [Standard Dose]----2件: 43, 44 💬
31Human normal immunoglobulin1件: Human immunoglobulin G---9件: 11, 13, 14, 43, 45, 50, 51, 63, 65 💬
32Hydroxychloroquine1件: Hydroxychloroquine1件: Hydroxychloroquine 💬--27件: 13, 34, 41, 43, 44, 45, 46, 48, 49, 53, 56, 63, 66, 84, 89, 90, 96, 97, 107, 218, 222, 224, 234, 254, 271, 298, 299 💬
33IFX-11件: Vilobelimab1件: Vilobelimab 💬1件: C5 💬11件: Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬3件: 43, 44, 269 💬
34Infliximab1件: Infliximab1件: Infliximab 💬1件: TNF 💬67件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬26件: 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
35Intravenous immunoglobulins (human immunoglobulins G)----1件: 43 💬
36Intravenous methyl prednisolone1件: Prednisolone1件: Prednisolone 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 43 💬
37MabThera1件: Rituximab1件: Rituximab 💬1件: MS4A1 💬1件: Hematopoietic cell lineage 💬22件: 11, 13, 14, 19, 35, 43, 44, 46, 49, 50, 51, 52, 53, 61, 63, 64, 65, 83, 93, 162, 222, 271 💬
38Mabthera®1件: Rituximab1件: Rituximab 💬1件: MS4A1 💬1件: Hematopoietic cell lineage 💬6件: 13, 35, 43, 44, 46, 93 💬
39MabThera® 100MG1件: Rituximab1件: Rituximab 💬1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 43 💬
40MabThera® 500MG1件: Rituximab1件: Rituximab 💬1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 43 💬
41Methotrexate1件: Methotrexate1件: Methotrexate 💬2件: DHFR,
DHFR2 💬		5件: Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬38件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331 💬
42Methyl prednisolone1件: Prednisolone1件: Prednisolone 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬3件: 43, 49, 96 💬
43Methylprednisolone1件: Methylprednisolone1件: Methylprednisolone 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬46件: 2, 11, 13, 14, 18, 19, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 62, 63, 64, 65, 66, 83, 84, 85, 86, 93, 95, 96, 97, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296 💬
44Methylprednisolone (or other glucocorticoid)1件: Methylprednisolone1件: Methylprednisolone 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 43 💬
45Mycophenolate1件: Mycophenolic acid1件: Mycophenolic acid 💬2件: IMPDH1,
IMPDH2 💬		4件: Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Purine metabolism 💬36件: 2, 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 49, 51, 53, 60, 61, 62, 65, 66, 84, 85, 93, 95, 96, 162, 164, 222, 224, 226, 228, 234, 283, 284, 285, 300 💬
46Mycophenolate mofetil2件: Mycophenolate mofetil,
Mycophenolic acid		2件: Mycophenolate mofetil ,
Mycophenolic acid 💬		2件: IMPDH1,
IMPDH2 💬		4件: Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Purine metabolism 💬34件: 2, 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 49, 51, 53, 60, 61, 62, 65, 66, 85, 93, 95, 96, 162, 164, 222, 224, 226, 234, 283, 284, 285, 300 💬
47Mycophenolate mofetil,methotrexate3件: Methotrexate,
Mycophenolate mofetil,
Mycophenolic acid		3件: Methotrexate ,
Mycophenolate mofetil ,
Mycophenolic acid 💬		4件: DHFR,
DHFR2,
IMPDH1,
IMPDH2 💬		8件: Antifolate resistance, Biosynthesis of cofactors, Drug metabolism - other enzymes, Folate biosynthesis, Metabolic pathways, Nucleotide metabolism, One carbon pool by folate, Purine metabolism 💬3件: 42, 43, 45 💬
48Mycophenolic acid1件: Mycophenolic acid1件: Mycophenolic acid 💬2件: IMPDH1,
IMPDH2 💬		4件: Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Purine metabolism 💬8件: 11, 43, 49, 51, 60, 66, 96, 222 💬
49Naltrexone1件: Naltrexone1件: Naltrexone 💬3件: OPRD1,
OPRK1,
OPRM1 💬		5件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬12件: 6, 10, 13, 40, 41, 42, 43, 44, 45, 96, 97, 226 💬
50NALTREXONE HYDROCHLORIDE1件: Naltrexone1件: Naltrexone 💬3件: OPRD1,
OPRK1,
OPRM1 💬		5件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬8件: 10, 40, 41, 42, 43, 44, 45, 96 💬
51Obinutuzumab1件: Obinutuzumab1件: Obinutuzumab 💬1件: MS4A1 💬1件: Hematopoietic cell lineage 💬4件: 43, 44, 49, 222 💬
52Pednisone----2件: 43, 44 💬
53Placebo (physiological saline)----2件: 43, 45 💬
54Plaquenil - Hydroxychloroquine 200mg Film coated tablets1件: Hydroxychloroquine1件: Hydroxychloroquine 💬--3件: 43, 44, 45 💬
55PREDNISOLONE1件: Prednisolone1件: Prednisolone 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬42件: 3, 11, 13, 14, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300 💬
56Prednison acis® 20 mg----2件: 43, 44 💬
57Prednison acis® 5 mg----2件: 43, 44 💬
58Prednison acis¿ 20 mg----2件: 43, 44 💬
59Prednison acis¿ 5 mg----2件: 43, 44 💬
60Prednisone1件: Prednisone1件: Prednisone 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬45件: 2, 11, 13, 14, 19, 26, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 61, 63, 64, 65, 66, 79, 81, 84, 85, 86, 95, 96, 97, 113, 162, 164, 205, 222, 224, 228, 283, 284, 288, 299, 300, 307, 331 💬
61Prednisone (and methylprednisolone)2件: Methylprednisolone,
Prednisone		2件: Methylprednisolone ,
Prednisone 💬		1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 43 💬
62PredniSONE Tablets, USP1件: Prednisone1件: Prednisone 💬1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬3件: 41, 43, 44 💬
63Prednisone, methylprednisolone,cyclophosphamides2件: Methylprednisolone,
Prednisone		2件: Methylprednisolone ,
Prednisone 💬		1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬3件: 42, 43, 45 💬
64Remission induction therapy----2件: 43, 44 💬
65RITUXIMAB1件: Rituximab1件: Rituximab 💬1件: MS4A1 💬1件: Hematopoietic cell lineage 💬48件: 11, 13, 14, 19, 26, 35, 36, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 52, 53, 55, 56, 60, 61, 63, 64, 65, 66, 83, 84, 85, 86, 93, 94, 96, 97, 162, 222, 229, 256, 271, 274, 283, 284, 285, 288, 296, 300, 331 💬
66Rituximab (Arm A)1件: Rituximab1件: Rituximab 💬1件: MS4A1 💬1件: Hematopoietic cell lineage 💬2件: 43, 44 💬
67Rituximab (Arm B)1件: Rituximab1件: Rituximab 💬1件: MS4A1 💬1件: Hematopoietic cell lineage 💬2件: 43, 44 💬
68RIXATHON 500mg----1件: 43 💬
69RO0452294/V01----2件: 43, 44 💬
70RO0452294/V02----3件: 35, 43, 44 💬
71Ro106-1443----1件: 43 💬
72Sendoxan----2件: 13, 43 💬
73Tocilizumab1件: Tocilizumab1件: Tocilizumab 💬1件: IL6R 💬12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬21件: 2, 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
74Vilobelimab1件: Vilobelimab1件: Vilobelimab 💬1件: C5 💬11件: Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬2件: 43, 44 💬
75Vitamin D2件: Cholecalciferol,
Vitamin D		1件: Cholecalciferol 💬1件: VDR 💬5件: Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬20件: 13, 19, 41, 43, 44, 46, 49, 50, 68, 93, 95, 96, 97, 179, 222, 228, 235, 274, 298, 299 💬